Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with heart failure (HF), but the direct cardiac effects of these drugs remain incompletely understood. Recent evidence has identified pantothenate kinase 1 (PANK1) as a direct cardiac target of SGLT2 inhibitors, whereby PANK1 activation can restore coenzyme A availability and myocardial metabolic capacity. This finding highlights the therapeutic potential of targeting the PANK1–coenzyme A axis in patients with HF.
Beyond glucose lowering and ketogenesis: unveiling new cardioprotective mechanisms of SGLT2 inhibitors / Riccio, A., Santulli, G.. - In: NATURE REVIEWS. CARDIOLOGY. - ISSN 1759-5002. - (2026). [10.1038/s41569-026-01357-w]
Beyond glucose lowering and ketogenesis: unveiling new cardioprotective mechanisms of SGLT2 inhibitors
Alessia RiccioPrimo
Writing – Original Draft Preparation
;
2026
Abstract
Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with heart failure (HF), but the direct cardiac effects of these drugs remain incompletely understood. Recent evidence has identified pantothenate kinase 1 (PANK1) as a direct cardiac target of SGLT2 inhibitors, whereby PANK1 activation can restore coenzyme A availability and myocardial metabolic capacity. This finding highlights the therapeutic potential of targeting the PANK1–coenzyme A axis in patients with HF.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
